2-(1,1-dimethoxyethyl)naphtho[2,3-b]furan-4,9-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: 2-(1,1-dimethoxyethyl)naphtho[2,3-b]furan-4,9-dione
• 英文别名: 2-(1,1-Dimethoxyethyl)benzo[f][1]benzofuran-4,9-dione；2-(1,1-dimethoxyethyl)benzo[f][1]benzofuran-4,9-dione
• 化学式: C₁₆H₁₄O₅
• 分子量: 286.284
• InChiKey: MXHANRIJLNQXQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(1,1-dimethoxyethyl)naphtho[2,3-b]furan-4,9-dione 、 tert-butyl N-(tert-butoxycarbonyl)-N-(2-isocyanatoethyl)glycinate 在 sodium dithionite 、 四丁基溴化铵 、 N,N-二异丙基乙胺 、 锌 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.17h， 以0.23 g的产率得到di-tert-butyl 2,2'-((((((2-(1,1-dimethoxyethyl)naphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis((tert-butoxycarbonyl)azanediyl))diacetate
  参考文献：
  名称：

  TW2016/39824

  摘要：

  公开号：
• 作为产物：
  描述：

  2-乙酰基呋喃并-1,4-萘醌 、 原甲酸三甲酯 在 对甲苯磺酸一水合物 作用下， 以 甲醇 为溶剂， 反应 3.5h， 以0.53 g的产率得到2-(1,1-dimethoxyethyl)naphtho[2,3-b]furan-4,9-dione
  参考文献：
  名称：

  TW2016/39824

  摘要：

  公开号：

文献信息

• Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US10183925B2

  公开（公告）日：2019-01-22

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(═O) B, —C(═O)CR3AR3BB, —CO2B, —C(═S)OB, —CONR3CB, —C(═S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.

  本发明提供了式(1A)代表的化合物或其药学上可接受的盐。由式(1A)代表的化合物或其药学上可接受的盐，其中A1和A2相同或不同，且各自独立地为-C(═O)B、-C(═O)CR3AR3BB、-CO2B、-C(═S)OB、-CONR3CB、-C(═S)NR3CB、氢原子或类似物，其中A1和A2并非都是氢原子、其中 B 是任选取代的 3 至 12 元单环或多环杂环基团，任选取代的 3 至 12 元环状氨基基团，或下式（B）所代表的基团，其中 3 至 12 元单环或多环杂环基团和 3 至 12 元环状氨基基团在环中至少有一个或多个仲氮原子；R1为氢原子或类似物；R2A、R2B、R2C 和 R2D 相同或不同，且各自独立地为氢原子或类似物；以及 R8 为烷基。 其中 * 表示键合位置。
• WATER-SOLUBLE PRODRUGS
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20180111914A1

  公开（公告）日：2018-04-26

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O) B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.
• SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20190084955A1

  公开（公告）日：2019-03-21

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O)B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.
• [EN] WATER-SOLUBLE PRODRUGS<br/>[FR] PROMÉDICAMENTS SOLUBLES DANS L'EAU
  申请人：BOSTON BIOMEDICAL INC

  公开号：WO2016157052A1

  公开（公告）日：2016-10-06

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently -C (=0) B, -C (=0) CR3AR3BB, -C02B, -C(=S)0B, -C0NR3CB, -C(=S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl.